Inhibikase Therapeutics Inc Earnings
The next earnings date for Inhibikase Therapeutics Inc has not yet been scheduled.
Analyst Estimates of Inhibikase Therapeutics Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Inhibikase Therapeutics Inc Earnings: Historical
| 08/11/2026 | After Market | $-0.11 | -22.22% |
| 05/13/2026 | --- | $-0.10 | -5.67% |
| 03/26/2026 | After Market | $-0.09 | 25.00% |
| 11/14/2025 | After Market | $-0.13 | 0.00% |
| 08/14/2025 | After Market | $-0.11 | -37.50% |
| 05/14/2025 | After Market | $-0.15 | -66.67% |
| 03/25/2025 | Before Market | $-0.17 | -101.73% |
| 11/14/2024 | Before Market | $-0.65 | -35.42% |
| 08/14/2024 | After Market | $-0.66 | 1.49% |
| 05/15/2024 | After Market | $-0.73 | 7.59% |
More About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
“Inhibikase Therapeutics Inc Earnings” Can Refer to the Inhibikase Therapeutics Inc Earnings Date
Some people say “Inhibikase Therapeutics Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Inhibikase Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Inhibikase Therapeutics Inc Stock on the Earnings Date
If you own Inhibikase Therapeutics Inc stock (IKT) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Inhibikase Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Inhibikase Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Inhibikase Therapeutics Inc Earnings
You can contact us any time if you would like to ask questions about Inhibikase Therapeutics Inc earnings or anything else related to the stock market.